Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2016’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)

The report reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Kidney Disease (Chronic Renal Failure) therapeutics and enlists all their major and minor projects

The report assesses Chronic Kidney Disease (Chronic Renal Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acceleron Pharma, Inc.

Angion Biomedica Corp.

Astellas Pharma Inc.

AstraZeneca Plc

Bayer AG

Bio-inRen

BioAegis Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cellmid Limited

Complexa, Inc.

CTI BioPharma Corp.

Evotec AG

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GNI Group Ltd.

Intercept Pharmaceuticals, Inc.

Lupin Limited

Navya Biologicals Pvt Ltd

Nippon Zoki Pharmaceutical Co., Ltd.

Novartis AG

Otsuka Holdings Co., Ltd.

Prismic Pharmaceuticals, Inc.

Prolong Pharmaceuticals, LLC

ProMetic Life Sciences Inc.

Reata Pharmaceuticals, Inc.

Red Glead Discovery AB

RegenMedTX, LLC

Resverlogix Corp.

Sphaera Pharma Pvt. Ltd.

Stelic Institute & Co., Inc.

Taisho Pharmaceutical Co., Ltd.

Thrasos Therapeutics Inc.

Toray Industries, Inc.

VBS Pharmaceuticals

Vicore Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Chronic Kidney Disease (Chronic Renal Failure) Overview 8

Therapeutics Development 9

Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview 9

Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis 10

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies 11

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes 14

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies 18

Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes 21

Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 22

Acceleron Pharma, Inc. 22

Angion Biomedica Corp. 23

Astellas Pharma Inc. 24

AstraZeneca Plc 25

Bayer AG 26

Bio-inRen 27

BioAegis Therapeutics, Inc. 28

Boehringer Ingelheim GmbH 29

Bristol-Myers Squibb Company 30

Cellmid Limited 31

Complexa, Inc. 32

CTI BioPharma Corp. 33

Evotec AG 34

F. Hoffmann-La Roche Ltd. 35

Gilead Sciences, Inc. 36

GNI Group Ltd. 37

Intercept Pharmaceuticals, Inc. 38

Lupin Limited 39

Navya Biologicals Pvt Ltd 40

Nippon Zoki Pharmaceutical Co., Ltd. 41

Novartis AG 42

Otsuka Holdings Co., Ltd. 43

Prismic Pharmaceuticals, Inc. 44

Prolong Pharmaceuticals, LLC 45

ProMetic Life Sciences Inc. 46

Reata Pharmaceuticals, Inc. 47

Red Glead Discovery AB 48

RegenMedTX, LLC 49

Resverlogix Corp. 50

Sphaera Pharma Pvt. Ltd. 51

Stelic Institute & Co., Inc. 52

Taisho Pharmaceutical Co., Ltd. 53

Thrasos Therapeutics Inc. 54

Toray Industries, Inc. 55

VBS Pharmaceuticals 56

Vicore Pharma AB 57

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 58

Assessment by Monotherapy Products 58

Assessment by Combination Products 59

Assessment by Target 60

Assessment by Mechanism of Action 64

Assessment by Route of Administration 68

Assessment by Molecule Type 70

Drug Profiles 72

(palmidrol + silibinin) - Drug Profile 72

ambrisentan - Drug Profile 73

ANG-3070 - Drug Profile 75

ANG-3281 - Drug Profile 76

ANG-3586 - Drug Profile 77

apabetalone - Drug Profile 78

AS-2444697 - Drug Profile 87

bardoxolone methyl - Drug Profile 88

BI-655088 - Drug Profile 93

BLR-400 - Drug Profile 94

BMS-986177 - Drug Profile 95

BRN-1889 - Drug Profile 96

C-21 - Drug Profile 97

CAB-101 - Drug Profile 99

calcium succinate - Drug Profile 100

CAR Peptide - Drug Profile 101

cardiotoxin - Drug Profile 102

Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile 103

CXA-10 - Drug Profile 104

dapagliflozin propanediol - Drug Profile 106

Drug for Kidney Diseases - Drug Profile 113

F-351 - Drug Profile 114

finerenone - Drug Profile 116

INT-767 - Drug Profile 118

KBP-5074 - Drug Profile 119

LHW-090 - Drug Profile 120

NAV-003 - Drug Profile 121

NZ-419 - Drug Profile 122

obinutuzumab - Drug Profile 123

pacritinib - Drug Profile 130

PBI-4050 - Drug Profile 141

PBI-4419 - Drug Profile 146

Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 147

Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 148

Sanguinate - Drug Profile 150

Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile 152

Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease and Hypertension - Drug Profile 153

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 154

Small Molecules for Chronic Kidney Disease - Drug Profile 155

Small Molecules for Chronic Kidney Disease - Drug Profile 156

Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile 157

sotatercept - Drug Profile 158

SP-20103 - Drug Profile 163

SPR-494 - Drug Profile 164

STNM-310 - Drug Profile 165

Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 166

Synthetic Peptides for Chronic Kidney Disease - Drug Profile 167

TNT-009 - Drug Profile 168

tolvaptan - Drug Profile 170

torsemide ER - Drug Profile 174

TRC-101 - Drug Profile 175

TS-143 - Drug Profile 176

Vida-5 - Drug Profile 177

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 178

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 181

Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 182

Featured News & Press Releases 182

Appendix 192

Methodology 192

Coverage 192

Secondary Research 192

Primary Research 192

Expert Panel Validation 192

Contact Us 192

Disclaimer 193

List of Tables

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2016 13

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Development by Companies, H2 2016 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Development, H2 2016 21

Products under Development by Companies, H2 2016 22

Products under Development by Companies, H2 2016 (Contd..1) 23

Products under Development by Companies, H2 2016 (Contd..2) 24

Products under Investigation by Universities/Institutes, H2 2016 25

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Acceleron Pharma, Inc., H2 2016 26

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Angion Biomedica Corp., H2 2016 27

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Astellas Pharma Inc., H2 2016 28

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by AstraZeneca Plc, H2 2016 29

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Bayer AG, H2 2016 30

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Bio-inRen, H2 2016 31

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by BioAegis Therapeutics, Inc., H2 2016 32

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 33

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Bristol-Myers Squibb Company, H2 2016 34

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Cellmid Limited, H2 2016 35

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Complexa, Inc., H2 2016 36

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by CTI BioPharma Corp., H2 2016 37

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Evotec AG, H2 2016 38

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 39

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Gilead Sciences, Inc., H2 2016 40

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by GNI Group Ltd., H2 2016 41

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 42

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Lupin Limited, H2 2016 43

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Navya Biologicals Pvt Ltd, H2 2016 44

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H2 2016 45

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Novartis AG, H2 2016 46

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Otsuka Holdings Co., Ltd., H2 2016 47

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Prismic Pharmaceuticals, Inc., H2 2016 48

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 49

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by ProMetic Life Sciences Inc., H2 2016 50

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Reata Pharmaceuticals, Inc., H2 2016 51

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Red Glead Discovery AB, H2 2016 52

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by RegenMedTX, LLC, H2 2016 53

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Resverlogix Corp., H2 2016 54

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016 55

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Stelic Institute & Co., Inc., H2 2016 56

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2016 57

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Thrasos Therapeutics Inc., H2 2016 58

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Toray Industries, Inc., H2 2016 59

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by VBS Pharmaceuticals, H2 2016 60

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Vicore Pharma AB, H2 2016 61

Assessment by Monotherapy Products, H2 2016 62

Assessment by Combination Products, H2 2016 63

Number of Products by Stage and Target, H2 2016 65

Number of Products by Stage and Mechanism of Action, H2 2016 69

Number of Products by Stage and Route of Administration, H2 2016 73

Number of Products by Stage and Molecule Type, H2 2016 75

Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects, H2 2016 182

Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects (Contd..1), H2 2016 183

Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects (Contd..2), H2 2016 184

Chronic Kidney Disease (Chronic Renal Failure) – Discontinued Products, H2 2016 185

List of Figures

List of Figures

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2016 13

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Products, H2 2016 21

Assessment by Monotherapy Products, H2 2016 62

Number of Products by Top 10 Targets, H2 2016 64

Number of Products by Stage and Top 10 Targets, H2 2016 64

Number of Products by Top 10 Mechanism of Actions, H2 2016 68

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 68

Number of Products by Routes of Administration, H2 2016 72

Number of Products by Stage and Routes of Administration, H2 2016 72

Number of Products by Molecule Types, H2 2016 74

Number of Products by Stage and Molecule Types, H2 2016 74

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports